Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 7Lymphoma, B-Cell 4Lymphoma, Follicular 3Lymphoma 3Lymphoma, Mantle-Cell 2Waldenstrom Macroglobulinemia 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

Rituximab 16zanubrutinib 12ibrutinib 9venetoclax 8Cyclophosphamide 8pirtobrutinib 5fludarabine phosphate 5Whole-Body Irradiation 5Sirolimus 5Mycophenolic Acid 5Bendamustine Hydrochloride 5acalabrutinib 4Peripheral Blood Stem Cell Transplantation 4Dexamethasone 4ixazomib 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Cyclosporine 3Bortezomib 3Biopsy 3fludarabine 2carfilzomib 2Tacrolimus 2Prednisone 2Melphalan 2Etoposide 2Cyclosporins 2Calcium Dobesilate 2CT-P10 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × loncastuximab tesirine × 1 year × Clear all
NCT05190705 2026-05-20

Loncastuximab Tesirine in WM

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
21 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡